Prevalence of hepatitis B surface antigen (HBsAg) in a blood donor population born prior to and after implementation of universal HBV vaccination in Shenzhen, China

BMC Infectious Diseases

Research Article

Xin Zheng¹  Zhen Wang²  Tingting Li²  Jean-Pierre Allain³  Chengyao Li⁴  Liang Lu⁵  Jinfeng Zeng⁵  Baocheng Yang⁵  Xiaoxuan Xu⁵  Weigang Zhu⁵  Xianlin Ye⁵ 

[1] Baoan Central Blood Station, Shenzhen, China;Department of Transfusion Medicine, Southern Medical University, 510515, Guangzhou, China;Department of Transfusion Medicine, Southern Medical University, 510515, Guangzhou, China;Department of Haematology, University of Cambridge, Cambridge, UK;Department of Transfusion Medicine, Southern Medical University, 510515, Guangzhou, China;School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China;Shenzhen Blood Center, Shenzhen, China;

关键词: HBV;    Prevalence;    Vaccination;    Blood donors;    China;   

DOI  :  10.1186/s12879-016-1834-2

 received in 2016-05-10, accepted in 2016-09-14,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundNeonatal hepatitis B vaccination program at birth has been implemented nationwide since 1992 in China. However, current HBV prevalence status in blood donors has not been entirely examined, which may impact HBV safety in blood donations as the vaccinees over 18 years old progressively become the majority population of blood donors.MethodsIn this study, 569,145 blood donors were screened for HBsAg by rapid tests and enzyme immunoassays, among them 475,538 blood samples with negative HBsAg were further screened for HBV DNA by nucleic acid testing between 2005 and 2014 at Shenzhen blood center.ResultsAn overall 2.3 % HBsAg prevalence was found in the blood donor population during the past 10 years (2.86 % in 2005, 1.76 % in 2010, and 2.79 % in 2014, respectively). HBsAg seroconversion occurred in 0.37 % of repeat-donors. When stratified by age, the prevalence of HBsAg was found significantly higher in younger donors age 18–25 years (2.73 %) than in those 26–35 years (2.13 %), 36–45 years (2.03 %) and 46–58 years (1.71 %) (P < 0.001), unexpectedly suggesting that younger donors remained at risk of chronic HBV infection. Assuming that donors aged 18–22 born before or after 1992 were non-vaccinated and vaccinated, respectively, HBsAg prevalence was higher in first-time donors born ≥1992 (3.9 %) than prior to 1992 (3.5 %, P = 0.005). The incidence of HBV infection in the 5-year period examined was significantly lower in repeat-donors born ≥1992 (0.27 %) than prior to 1992 (0.6 %, P = 0.008). The yield of HBV DNA+/HBsAg- donors was 1:3,302, including 1:4,486 occult infections and 1:43,231 window period infections.ConclusionYoung blood donors born after implementation of universal HBV vaccination in China presented higher prevalence of HBsAg but lower incidence of HBsAg seroconversion than older, presumed unvaccinated, donors. HBV vaccine boosting for adolescents at 15–17 years old prior to reaching blood donor age might help improve blood safety.

【 授权许可】

CC BY   
© The Author(s). 2016